Drugged Returns

Updated on: 7 February 2024 6:09 pm

Drugged Returns

		Annual US sales
Fluoxetine	Dr Reddy’s share fell from 50 to 30 per cent in three years	$1.8 billion
Carbamazepine	Sun Pharma’s one per cent share is due to its focus on antidepressants and lack of scale	$70 million
Citalopram	Dr Reddy’s share of 15 per cent is limited due to competition and the presence of larger MNCs	$1.4 billion
Metformin	Ranbaxy’s share of two per cent is because it entered in 2005	$1 billion
Enalapril	Despite being early entrants, Ranbaxy and Wockhardt couldn't garner more than 10 per cent share each	$500 million
Captopril	Wockhardt has a negligible share as it was a late entrant	$150 million